CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CAR T cell-mediated bone marrow inflammation causes hematotoxicity and favors clonal hematopoiesis.
CAR T cell-mediated bone marrow inflammation causes hematotoxicity and favors clonal hematopoiesis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
尽管嵌合抗原受体(CAR)T细胞治疗血液系统恶性肿瘤效果显著,但也会引起副作用。接受CAR-T 治疗的患者可能发生持续性血细胞减少或血液毒性。本研究采用免疫功能完整的小鼠模型重现血液毒性,并证明单独使用淋巴细胞清除方案不足以诱发血液毒性,必须同时注射CAR-T 细胞。对发生血液毒性患者的骨髓(BM)样本分析显示,骨髓CAR-T 细胞与血液毒性严重程度相关。CAR-T 细胞呈现活化状态,导致强烈炎症。此外,我们在患者队列中观察到较高比例的克隆性造血,并发现CAR-T 细胞注射后数月内出现不同的造血克隆。本研究为血液毒性的病理生理机制提供了见解,并强调需要开展长期随访研究,以确定这种强烈骨髓炎症对克隆选择的影响。
Although chimeric antigen receptor (CAR) T cells have shown excellent results in treating hematological malignancies, they also cause side effects. Patients treated with CAR T cells experience persistent cytopenia or hematotox.
Here, using a fully immunocompetent mouse model, we recapitulated hematotox and demonstrated that a lymphodepleting regimen alone was insufficient to induce hematotox and required CAR T cell injection. Analysis of bone marrow (BM) samples from patients experiencing hematotox revealed a correlation between BM CAR T cells and hematotox severity. CAR T cells exhibited an activated program, leading to intense inflammation.
In addition, we observed a high rate of clonal hematopoiesis in our patient cohort and the emergence of distinct hematopoietic clones in the months after CAR T cell injection.
Our study provides insights into the pathophysiology of hematotox and highlights the need for long-term follow-up studies to determine the relevance of this intense BM inflammation in clonal selection.
MEMBER ACCOUNT
登录成功会直接打开下一页。